
ASX Announcement and Media Release

6 June 2005

SciGen Limited

SciGen announces senior management change and relocation

The Directors of SciGen Limited ["SciGen" or the "Company"] announced today that the Managing Director and Chief Executive Officer of the Company, Mr Mark Compton, would leave the Company on 5 August, 2005. Mr Compton's departure from the Company is by mutual agreement and follows a review of the current structure of the Company and its future needs in terms of management by and location of the CEO.

Mr Paul Freiman Chairman of SciGen said "the Board believes that with the expanding business of SciGen in the pharmaceutical industry and its growing business in Asia, it would better suit the Company to have a career pharma CEO based closer to our expanding markets. The Company has been very fortunate to have the services of Mr Compton as Managing Director and CEO before and since its listing on the ASX. Mr Compton was responsible for SciGen's A\$30M recapitalisation and public listing on the ASX in late 2002 along with his contribution to significantly growing the revenue stream of the business over the last 3 years, whilst putting the internal processes in place necessary for a publicly listed company. Mr Compton's departure is being effected on an entirely amicable basis and all terms surrounding his departure have been agreed."

Mr Freiman also noted that "The Board is embarking upon a search for a new CEO who is likely to be based in Asia. Mr Compton has kindly agreed to remain in his position for the next 2 months to assist with the transition, although he may stand down from the board prior to his actual departure from the Company."

"SciGen is a Singaporean incorporated entity and is listed on the ASX. It is not envisaged that these arrangements will change for the foreseeable future" Mr Freiman said.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Sri Lanka, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO: Telephone: +61 2 9234 1700: Web: www.scigen.com.au